Weld Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Weld Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-38,541	Closed	-$500K	–	1040
2019 Q2	$500K	Buy	38,541 +24,380	+172%	+$307K	0.09%	383
2019 Q1	$223K	Sell	14,161 -14,026	-50%	-$243K	0.04%	570
2018 Q4	$567K	Buy	+28,187	New	+$621K	0.13%	303

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Weld Capital Management's RVNC Position: Q3 2019 in Review

Weld Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2019, closing a stake of 38,541 shares — an estimated $500K sold.

Weld Capital Management first reported a position in RVNC in Q4 2018 and held it in 3 quarters. The position peaked at $567K in Q4 2018. 109 funds tracked by Wall St. Rank hold RVNC as of Q3 2019.

Weld Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Weld Capital Management sold 38,541 Revance Therapeutics, Inc. shares in Q3 2019, an estimated $500K.
Weld Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2018 and held it in 3 quarters.
Weld Capital Management's Revance Therapeutics, Inc. position peaked at $567K in Q4 2018.
109 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2019.

Based on Weld Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.